Clinical trial
Phase II Study of Pandemic Influenza Vaccine
NCT00320346 · Seqirus, Industry · Completed
Key facts
| NCT number | NCT00320346 |
|---|---|
| Title | Phase II Study of Pandemic Influenza Vaccine |
| Official title | A Double-Blind, Randomised, Multi-Centre Study to Evaluate the Safety, Tolerability, Immunogenicity and Lot to Lot Consistency of Two Formulations of CSL Limited's Inactivated Prototype Pandemic Influenza Vaccine in a Healthy Adult Population (≤18 Years to ≥64 Years of Age). |
| Lead sponsor | Seqirus, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Influenza |
| Intervention type | Biological |
| Interventions | Pandemic Influenza Vaccine |
| Enrollment | 400 |
| Start date | Jul 1, 2006 |
| Completion | Sep 1, 2006 |
| First posted | May 3, 2006 |
| Last update posted | Jul 19, 2016 |
| Countries | Australia |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: